Codexis, Inc. (CDXS) is a publicly traded Healthcare sector company. As of May 20, 2026, CDXS trades at $2.48 with a market cap of $231.79M and a P/E ratio of -6.99. CDXS moved +2.03% today. Year to date, CDXS is +52.80%; over the trailing twelve months it is +1.23%. Its 52-week range spans $0.96 to $6.08. Analyst consensus is strong buy with an average price target of $6.90. Rallies surfaces CDXS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Codexis Achieves First Full-Length siRNA Synthesis with Stereochemistry Control and Cuts GWP by Over 50%: Codexis presented new data demonstrating full-length siRNA synthesis with precise phosphorothioate stereochemistry control via its ECO Synthesis platform at TIDES USA 2026. It also unveiled single-nucleotide initiation for enzymatic RNA synthesis and reported over 50% reduction in global warming potential plus 2.7-fold lower GWP on an input materials basis.
| Metric | Value |
|---|---|
| Price | $2.48 |
| Market Cap | $231.79M |
| P/E Ratio | -6.99 |
| EPS | $-0.35 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.08 |
| 52-Week Low | $0.96 |
| Volume | 286.77K |
| Avg Volume | 0 |
| Revenue (TTM) | $78.09M |
| Net Income | $-31.99M |
| Gross Margin | 88.90% |
5 analysts cover CDXS: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.90.